Jantunen E, Lahtinen R, Laakso M
Department of Medicine, Kuopio University Hospital, Finland.
Leuk Lymphoma. 1995 Oct;19(3-4):207-11. doi: 10.3109/10428199509107890.
Multiple myeloma is characterized by bone disease including osteoporosis, osteolytic lesions, pathological fractures and hypercalcaemia leading to pain, immobilization and decrease in the quality of life. Clodronate, a bisphosphonate, has been shown to be effective in the treatment of hypercalcaemia in patients with multiple myeloma. In addition, clodronate reduces the progression of osteolytic lesions and the amount of vertebral fractures and may also relieve pain in these patients. Recent studies suggest that oral clodronate should be considered in the adjunctive treatment of all patients with active multiple myeloma independently of the presence of bone lesions at diagnosis. Due to its safety and efficacy, clodronate seems to have gained an important role in the management of patients with multiple myeloma.
多发性骨髓瘤的特征是骨病，包括骨质疏松、溶骨性病变、病理性骨折和高钙血症，可导致疼痛、活动受限及生活质量下降。氯膦酸盐，一种双膦酸盐，已被证明对治疗多发性骨髓瘤患者的高钙血症有效。此外，氯膦酸盐可减缓溶骨性病变的进展，减少椎体骨折的数量，还可能缓解这些患者的疼痛。最近的研究表明，对于所有活动性多发性骨髓瘤患者，无论诊断时是否存在骨病变，均应考虑口服氯膦酸盐进行辅助治疗。由于其安全性和有效性，氯膦酸盐似乎在多发性骨髓瘤患者的管理中发挥了重要作用。
